Get the Stockscreener App
0.7224
4.62%
-0.035
Pre-market:
.72
-0.0024
-0.33%
Tenaya Therapeutics Inc stock is traded at $0.7224, with a volume of 3.69M.
It is down -4.62% in the last 24 hours and up +20.00% over the past month.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
See More
Previous Close:
$0.7574
Open:
$0.7792
24h Volume:
3.69M
Relative Volume:
0.81
Market Cap:
$156.76M
Revenue:
-
Net Income/Loss:
$-90.60M
P/E Ratio:
-1.1525
EPS:
-0.6268
Net Cash Flow:
$-68.88M
1W Performance:
-12.17%
1M Performance:
+20.00%
6M Performance:
-51.52%
1Y Performance:
+10.51%
1-Day Range:
$0.721
$0.804
1-Week Range:
$0.718
$0.8315
52-Week Range:
$0.36
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.7224 | 164.35M | 0 | -90.60M | -68.88M | -0.6268 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
William Blair analysts confident on Tenaya Therapeutics (TNYA) product pipeline - MSN
William Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product Pipeline - Yahoo Finance
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - MSN
Tenaya Therapeutics, Inc. (TNYA) reports Q4 EPS of (12c), in line with consensus - MSN
Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus - Insider Monkey
TNYA pulls back after hours following significant $1.13B deal-spurred rally - MSN
symbol__ Stock Quote Price and Forecast - CNN
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Tenaya Therapeutics (NASDAQ:TNYA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
How TN-301 Progress And Alnylam Deal At Tenaya Therapeutics (TNYA) Has Changed Its Investment Story - simplywall.st
What is Lifesci Capital's Estimate for TNYA Q1 Earnings? - MarketBeat
Outperform Maintained on Tenaya Therapeutics (TNYA) by Leerink and William Blair March 2026 - Meyka
Tenaya Therapeutics (TNYA) Valuation After TN-301 Data And New Alnylam Collaboration - simplywall.st
William Blair reiterates Outperform on Tenaya Therapeutics stock - Investing.com Australia
William Blair reiterates Outperform on Tenaya Therapeutics stock By Investing.com - Investing.com South Africa
Leerink Partners reiterates Outperform on Tenaya stock at $2 - Investing.com UK
Chardan Capital Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA) - MarketBeat
Tenaya Therapeutics Reports Promising 2025 Results, Advances Gene Therapy Programs, and Extends Cash Runway Into 2027 - Minichart
Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal - Yahoo Finance
Tenaya Therapeutics: Advancing Genetic Medicines and Small Molecule Therapies for Heart Disease Treatment - Minichart
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
Tenaya Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027 - TradingView
Tenaya Therapeutics (NASDAQ:TNYA) Issues Earnings Results, Meets Expectations - MarketBeat
Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
TNYA: Clinical progress, Alnylam deal, and financing extend cash runway into 2027 - TradingView
Tenaya Therapeutics (NASDAQ: TNYA) narrows 2025 loss and extends cash runway to 2027 - Stock Titan
Q4 and 2025 results drive business momentum, Tenaya Therapeutics outlines - Traders Union
BRIEF-Tenaya Therapeutics Q4 Net Income USD -20.175 Million Vs. IBES Estimate USD -22 Million - TradingView
Heart gene therapy data and $1.1B Alnylam deal help Tenaya fund work to 2027 - Stock Titan
Tenaya Therapeutics Soars with Major Collaboration Deal - timothysykes.com
Tenaya Therapeutics Reports TN-301 Outperforms Givinostat in Enhancing Muscle Function and Addressing DMD Cardiomyopathy - Quiver Quantitative
Experimental drug TN-301 restores muscle strength in Duchenne mice - Stock Titan
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 - GlobeNewswire
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy - Bitget
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Partnership With Tenaya Therapeutics - Sahm
Leerink Partners Global Biopharma Conference 2026: TEVA, CYTK, IMRX, TNYA And More Set To Present - RTTNews
Morgan Stanley reduces PT on Tenaya Therapeutics (TNYA), keeps constructive stance on US small- to mid-cap biotech - MSN
Tenaya Therapeutics, Inc.Common Stock (NQ: TNYA - The Chronicle-Journal
Tenaya Therapeutics announces orderly board leadership transition - MSN
Lifesci Capital Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Strong-Buy - MarketBeat
Hedge Fund Bets: Can Tenaya Therapeutics Inc lead its sector in growth2025 Market Sentiment & Precise Swing Trade Alerts - baoquankhu1.vn
Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets - BioWorld MedTech
Tenaya Therapeutics inks $1 billion-plus research deal with Alnylam - The Pharma Letter
Tenaya Therapeutics Stock Jumps After New Alnylam Deal - Sahm
TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally - Asianet Newsable
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):